Nektar Therapeutics Restricted Cash and Cash Equivalents
Nektar Therapeutics (NKTR) had Restricted Cash and Cash Equivalents of $25.00 million as of 2014-12-31, per its 10-K filed 2015-02-26.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2015-02-26
- 2014-12-31: Restricted Cash and Cash Equivalents $25.00M.
- 2014-09-30: Restricted Cash and Cash Equivalents $25.00M.
- 2013-12-31: Restricted Cash and Cash Equivalents $25.00M.
- 2012-07-11: Restricted Cash and Cash Equivalents $25.00M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2014-12-31 | $25.00M 10-K · filed 2015-02-26 |
| 2014-09-30 | $25.00M 10-Q · filed 2014-11-07 |
| 2013-12-31 | $25.00M 10-K · filed 2015-02-26 |
| 2012-07-11 | $25.00M 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |